ImmunoGen, Inc. financial data

Symbol
IMGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
830 Winter St, Waltham, Massachusetts
State of incorporation
Massachusetts
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 439 % -1.84%
Debt-to-equity 63.4 % -7.77%
Return On Equity -22.1 % +70.9%
Return On Assets -13.5 % +69.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 266 M shares +20.6%
Common Stock, Shares, Outstanding 266 M shares +20.5%
Entity Public Float 990 M USD -24.7%
Common Stock, Value, Issued 2.44 M USD +10.3%
Weighted Average Number of Shares Outstanding, Basic 273 M shares +7.82%
Weighted Average Number of Shares Outstanding, Diluted 288 M shares +13.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 208 M USD +1.91%
Operating Income (Loss) -80.2 M USD +59.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 29.6 M USD
Income Tax Expense (Benefit) -1.17 M USD
Net Income (Loss) Attributable to Parent -73.5 M USD +63.4%
Earnings Per Share, Basic -0.31 USD/shares +62.7%
Earnings Per Share, Diluted 0.1 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 606 M USD +95.6%
Inventory, Net 5.5 M USD
Assets, Current 767 M USD +132%
Property, Plant and Equipment, Net 4.43 M USD -0.96%
Operating Lease, Right-of-Use Asset 8.34 M USD -22.9%
Other Assets, Noncurrent 14.2 M USD +8.08%
Assets 822 M USD +129%
Accounts Payable, Current 24.9 M USD +23.2%
Employee-related Liabilities, Current 15.2 M USD +75.8%
Contract with Customer, Liability, Current 37.2 M USD +147%
Liabilities, Current 135 M USD +29.9%
Contract with Customer, Liability, Noncurrent 26.7 M USD -31%
Operating Lease, Liability, Noncurrent 7.76 M USD -36.5%
Other Liabilities, Noncurrent 2.8 M USD +833%
Liabilities 261 M USD +44.1%
Retained Earnings (Accumulated Deficit) -1.71 B USD -4.5%
Stockholders' Equity Attributable to Parent 562 M USD +215%
Liabilities and Equity 822 M USD +129%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -73.7 M USD -78.1%
Net Cash Provided by (Used in) Financing Activities 620 K USD -98.2%
Net Cash Provided by (Used in) Investing Activities -209 K USD +31.9%
Common Stock, Shares Authorized 600 M shares 0%
Common Stock, Shares, Issued 266 M shares +20.4%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -73.9 M USD -79.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 606 M USD +95.6%
Deferred Tax Assets, Valuation Allowance 334 M USD -18.5%
Deferred Tax Assets, Gross 337 M USD -18.4%
Operating Lease, Liability 15.2 M USD -18.8%
Payments to Acquire Property, Plant, and Equipment 209 K USD -31.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -240 M USD -85.3%
Lessee, Operating Lease, Liability, to be Paid 18 M USD -22.9%
Property, Plant and Equipment, Gross 35.7 M USD +4.05%
Operating Lease, Liability, Current 4.46 M USD +12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.52 M USD +0.35%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.5 M USD +2.61%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.77 M USD -39.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.54 M USD +0.38%
Deferred Tax Assets, Operating Loss Carryforwards 115 M USD -56.5%
Preferred Stock, Shares Issued 22 K shares
Preferred Stock, Shares Authorized 5 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.43 M USD -74.2%
Operating Lease, Payments 1.2 M USD -14.3%
Preferred Stock, Shares Outstanding 22 K shares
Depreciation, Depletion and Amortization 448 K USD -5.29%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%